Sara Christina Meyer

7PUBLICATIONS
79CO-AUTHORS
PharmacogenomicsCardiovascular medicine and haematology not elsewhere classifiedMedical molecular engineering of nucleic acids and proteinsMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 24, 2026
Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

|Feb 28, 2026
Can hyperleukocytosis be caused by a non-hematologic condition? A 10-year retrospective tertiary-care center cohort study.

Elisavet Moutzouri, Emmanuel Häfliger, Katarzyna Aleksandra Jalowiec

|Jan 10, 2026
Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms.

Matthias Christen, Domenic Kaderli, Milos Ratknic

|Jan 17, 2024
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.

Andrew J Dunbar, Robert L Bowman, Young C Park

|Nov 22, 2023
Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.

Tamara Codilupi, Jakub Szybinski, Stefanie Arunasalam

|Sep 04, 2021
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.

Sime Brkic, Simona Stivala, Alice Santopolo

Pageof 2

Frequent Collaborators

3 joint publications

Alicia Rovo

3 joint publications

Anne Angelillo-Scherrer

3 joint publications

Ross L Levine

2 joint publications

Julie L Yang